

Lenka Fialová

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1503307/publications.pdf>

Version: 2024-02-01

35
papers

1,614
citations

394286

19
h-index

395590

33
g-index

40
all docs

40
docs citations

40
times ranked

2846
citing authors

#	ARTICLE	IF	CITATIONS
1	Levels and avidities of antiphosphatidylethanolamine antibodies in patients with thrombotic events and immunologically-mediated diseases. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2023, 167, 254-262.	0.2	0
2	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	0.9	14
3	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	0.6	8
4	Avidity of anti-phospholipid antibodies in relation to their levels. Central-European Journal of Immunology, 2020, 45, 136-143.	0.4	1
5	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
6	Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer’s Disease. Journal of Alzheimer's Disease, 2018, 64, 751-760.	1.2	20
7	Comparison of different enzyme–linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies. Journal of Clinical Laboratory Analysis, 2017, 31, .	0.9	21
8	Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2017, 161, 179-186.	0.2	4
9	Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2017, 161, 286-295.	0.2	9
10	Avidity of anticardiolipin antibodies-A factor that could be important for their detection by ELISA methods. Journal of Applied Biomedicine, 2014, 12, 277-284.	0.6	2
11	Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. Journal of Neuroimmunology, 2013, 262, 113-120.	1.1	47
12	Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis. Journal of Neuroimmunology, 2013, 259, 81-87.	1.1	21
13	Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. Journal of Neuroimmunology, 2012, 252, 100-105.	1.1	45
14	Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiologica, 2012, 57, 415-419.	1.1	11
15	Iron stores are associated with asymptomatic atherosclerosis in healthy men of primary prevention. European Journal of Clinical Investigation, 2011, 41, 846-853.	1.7	26
16	Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis. PLoS ONE, 2011, 6, e27476.	1.1	23
17	Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. European Journal of Neurology, 2010, 17, 23-30.	1.7	49
18	Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2010, 17, 562-566.	1.7	42

#	ARTICLE	IF	CITATIONS
19	Relationship between Increased Body Iron Stores, Oxidative Stress and Insulin Resistance in Healthy Men. <i>Annals of Nutrition and Metabolism</i> , 2009, 54, 268-274.	1.0	40
20	Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2008, 15, 1173-1179.	1.7	18
21	Antibodies against light neurofilaments in multiple sclerosis patients. <i>Acta Neurologica Scandinavica</i> , 2007, 116, 100-107.	1.0	40
22	Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 20-25.	1.8	53
23	Tu-P10:421 Antibodies to chlamydia pneumoniae in acute and chronic phase of myocardial infarction treated with PTCA. <i>Atherosclerosis Supplements</i> , 2006, 7, 277.	1.2	0
24	Oxidative stress and inflammation in pregnancy. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006, 66, 121-128.	0.6	60
25	Relationship of Pregnancy-Associated Plasma Protein-A to Renal Function and Dialysis Modalities. <i>Kidney and Blood Pressure Research</i> , 2004, 27, 88-95.	0.9	40
26	Increased Levels of Pregnancy-Associated Plasma Protein A Are Associated with Mortality in Hemodialysis Patients: Preliminary Results. <i>Blood Purification</i> , 2004, 22, 298-300.	0.9	25
27	Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. <i>Kidney International</i> , 2003, 63, S62-S64.	2.6	21
28	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. <i>Atherosclerosis</i> , 2003, 166, 195-196.	0.4	8
29	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. <i>American Heart Journal</i> , 2003, 146, 1060-1063.	1.2	26
30	Antiphospholipid Antibodies in Patients with Lupus Nephritis. <i>Renal Failure</i> , 2003, 25, 747-758.	0.8	6
31	Glycoxidation and inflammation in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 2577-2581.	0.4	47
32	Oxidative stress, metabolism of ethanol and alcohol-related diseases. <i>Journal of Biomedical Science</i> , 2001, 8, 59-70.	2.6	273
33	Ethanol and Oxidative Stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	1.4	93
34	Ethanol and oxidative stress. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 237S-243S.	1.4	48
35	Oxidative stress, metabolism of ethanol and alcohol-related diseases. , 2001, 8, 59.		15